Sensus Healthcare, Inc.
SRTSHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Sensus Healthcare, Inc. focuses on Medical Devices services and products. Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. At a $48.6M market cap, Sensus Healthcare, Inc. ranks as a micro-cap company within healthcare. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices.
Market Cap
$48.6M
Beta
1.19
P/E (TTM)
—
P/E (Fwd)
-17.02
EPS (TTM)
$-0.97
EPS (Fwd)
$-0.17
ROE
-34.8%
ROA
-16.6%
Cash
$15.2M
Total Debt
$343,000
Free CF
-$2.1M
52W Change
-11.7%
Annual Financials
Cash vs Debt
Where SRTS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SRTS finished 16.62% below its 150-day moving average ($3.31) and 23.76% below its 200-day moving average ($3.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SRTS overbought or oversold?
At the October 20, 2026 close, SRTS's RSI(14) was 20.8, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $15.2M in cash comfortably exceeding the $343K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$2.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -34.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $44.5M (2022) to $27.5M (2025), a 38% decline worth watching.
With cash comfortably exceeding debt, SRTS has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SRTS.